{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-040225","form_type":"8-K","ticker":"MLYS","cik":"0001933414","company_name":"Mineralys Therapeutics, Inc.","filed_at":"2026-06-03T20:07:02+00:00","discovered_at":"2026-06-03T20:08:01.267557+00:00","generated_at":"2026-06-03T20:36:02.025309+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mineralys prices $150M common stock offering at $26.50/sh; proceeds to fund royalty repurchase","bullets":["5,660,378 shares at $26.50/share; gross proceeds ~$150M, net ~$142.5M.","Proceeds to partially fund $200M upfront payment to repurchase royalty obligation from Tanabe Pharma.","Offering expected to close June 4, 2026; joint book-runners: BofA, Goldman Sachs, Evercore ISI.","Company separately announced a $500M committed debt facility with Pharmakon Advisors.","Underwriters purchased at $25.3075/share; shelf registration effective on filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-040225","json":"https://secwatch.observer/filing/0001628280-26-040225.json","markdown":"https://secwatch.observer/filing/0001628280-26-040225.md","text":"https://secwatch.observer/filing/0001628280-26-040225.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1933414/000162828026040225/0001628280-26-040225-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1933414/000162828026040225/mlys-20260603.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T20:36:02.025309+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}